Recurrent sustained atrial arrhythmias and thromboembolism in Fontan patients with total cavopulmonary connection.

AAD, anti-arrhythmic drug therapy Atrial arrhythmia Fontan operation TCPC, total cavopulmonary connection Thromboembolic complication Total cavopulmonary connection

Journal

International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 02 01 2021
revised: 25 02 2021
accepted: 27 02 2021
entrez: 31 3 2021
pubmed: 1 4 2021
medline: 1 4 2021
Statut: epublish

Résumé

Total cavopulmonary connection (TCPC) is associated with a lower risk of incident atrial arrhythmias as compared to atriopulmonary Fontan, but the risk of recurrent atrial arrhythmias is unknown in this population. The purpose of this study was to determine the incidence and risk factors for recurrent atrial arrhythmias and thromboembolic complications in patients with TCPC. This is a retrospective multicenter study conducted by the Alliance for Adult Research in Congenital Cardiology (AARCC), 2000-2018. The inclusion criteria were TCPC patients (age > 15 years) with prior history of atrial arrhythmia. A total of 103 patients (age 26 ± 7 years; male 58 [56%]) met inclusion criteria. The mean age at initial arrhythmia diagnosis was 13 ± 5 years, and atrial arrhythmias were classified as atrial flutter/tachycardia in 85 (83%) and atrial fibrillation in 18 (17%). The median duration of follow-up from the first episode of atrial arrhythmia was 14.9 (12.1-17.3) years, and during this period 64 (62%) patients had recurrent atrial arrhythmias (atrial flutter/tachycardia 51 [80%] and atrial fibrillation 13 [20%]) with annual incidence of 4.4%. Older age was a risk factor for arrhythmia recurrence while the use of a class III anti-arrhythmic drug was associated with a lower risk of recurrent arrhythmias. The incidence of thromboembolic complication was 0.6% per year, and the cumulative incidence was 4% and 7% at 5 and 10 years respectively from the time of first atrial arrhythmia diagnosis. There were no identifiable risk factors for thromboembolic complications in this cohort. Although TCPC provides superior flow dynamics and lower risk of incident atrial arrhythmias, there is a significant risk of recurrent arrhythmias among TCPC patients with a prior history of atrial arrhythmias. These patients may require more intensive arrhythmia surveillance as compared to other TCPC patients.

Sections du résumé

BACKGROUND BACKGROUND
Total cavopulmonary connection (TCPC) is associated with a lower risk of incident atrial arrhythmias as compared to atriopulmonary Fontan, but the risk of recurrent atrial arrhythmias is unknown in this population. The purpose of this study was to determine the incidence and risk factors for recurrent atrial arrhythmias and thromboembolic complications in patients with TCPC.
METHODS METHODS
This is a retrospective multicenter study conducted by the Alliance for Adult Research in Congenital Cardiology (AARCC), 2000-2018. The inclusion criteria were TCPC patients (age > 15 years) with prior history of atrial arrhythmia.
RESULTS RESULTS
A total of 103 patients (age 26 ± 7 years; male 58 [56%]) met inclusion criteria. The mean age at initial arrhythmia diagnosis was 13 ± 5 years, and atrial arrhythmias were classified as atrial flutter/tachycardia in 85 (83%) and atrial fibrillation in 18 (17%). The median duration of follow-up from the first episode of atrial arrhythmia was 14.9 (12.1-17.3) years, and during this period 64 (62%) patients had recurrent atrial arrhythmias (atrial flutter/tachycardia 51 [80%] and atrial fibrillation 13 [20%]) with annual incidence of 4.4%. Older age was a risk factor for arrhythmia recurrence while the use of a class III anti-arrhythmic drug was associated with a lower risk of recurrent arrhythmias. The incidence of thromboembolic complication was 0.6% per year, and the cumulative incidence was 4% and 7% at 5 and 10 years respectively from the time of first atrial arrhythmia diagnosis. There were no identifiable risk factors for thromboembolic complications in this cohort.
CONCLUSIONS CONCLUSIONS
Although TCPC provides superior flow dynamics and lower risk of incident atrial arrhythmias, there is a significant risk of recurrent arrhythmias among TCPC patients with a prior history of atrial arrhythmias. These patients may require more intensive arrhythmia surveillance as compared to other TCPC patients.

Identifiants

pubmed: 33786365
doi: 10.1016/j.ijcha.2021.100754
pii: S2352-9067(21)00042-7
pmc: PMC7988316
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100754

Informations de copyright

© 2021 The Author(s).

Références

J Am Coll Cardiol. 2011 Aug 2;58(6):645-51
pubmed: 21798429
Congenit Heart Dis. 2010 Sep-Oct;5(5):430-4
pubmed: 21087427
J Am Coll Cardiol. 2016 Sep 20;68(12):1312-9
pubmed: 27634123
Ann Thorac Surg. 2002 Aug;74(2):556-62
pubmed: 12173844
Circulation. 2018 Oct 23;138(17):1879-1896
pubmed: 30354657
J Thorac Cardiovasc Surg. 1988 Nov;96(5):682-95
pubmed: 3184963
Am Heart J. 2017 Jan;183:10-17
pubmed: 27979032
Int J Cardiol. 2005 Jul 20;102(3):509-13
pubmed: 16004898
Circ Arrhythm Electrophysiol. 2015 Apr;8(2):318-25
pubmed: 25583982
Heart Rhythm. 2014 Oct;11(10):e102-65
pubmed: 24814377
J Thorac Cardiovasc Surg. 1990 Aug;100(2):228-32
pubmed: 2143549
Eur J Cardiothorac Surg. 2015 Dec;48(6):825-32; discussion 832
pubmed: 25769469
J Am Coll Cardiol. 2019 Aug 27;74(8):1071-1081
pubmed: 31439217
Eur J Cardiothorac Surg. 2014 Sep;46(3):465-73; discussion 473
pubmed: 24578409
J Thorac Cardiovasc Surg. 2014 Aug;148(2):566-75
pubmed: 24280718
Eur J Cardiothorac Surg. 2016 Oct;50(4):632-641
pubmed: 27009106
J Thorac Cardiovasc Surg. 2005 Mar;129(3):569-75
pubmed: 15746740
Ann Thorac Surg. 2016 Feb;101(2):717-24
pubmed: 26602004
Int J Cardiol. 2016 Apr 1;208:115-9
pubmed: 26849685
Am Heart J. 2017 Apr;186:12-20
pubmed: 28454826
Br J Cancer. 2011 Feb 15;104(4):693-9
pubmed: 21266980

Auteurs

Alexander C Egbe (AC)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, United States.

William R Miranda (WR)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, United States.

Janaki Devara (J)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, United States.

Likhita Shaik (L)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, United States.

Momina Iftikhar (M)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, United States.

Ahmed Goda Sakr (A)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, United States.

Anitha John (A)

Children's National Hospital, Washington DC, United States.

Ari Cedars (A)

University of Texas, Southwestern Medical Center, United States.

Fred Rodriguez (F)

Emory University Hospital and Children's Healthcare of Atlanta, GA, United States.

Jeremy P Moore (JP)

Ahmanson/UCLA Adult Congenital Heart Disease Center, UCLA Medical Center, Los Angeles, CA, United States.

Matthew Russell (M)

Ahmanson/UCLA Adult Congenital Heart Disease Center, UCLA Medical Center, Los Angeles, CA, United States.

Jasmine Grewal (J)

University of British Columbia, Vancouver, United States.

Salil Ginde (S)

Children's Hospital Wisconsin, United States.

Adam M Lubert (AM)

Cincinnati Children's Hospital, OH, United States.

Heidi M Connolly (HM)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, United States.

Classifications MeSH